Jaime Imitola, MDProfessor of Neurology, Genetics and Genome Sciences, and NeuroscienceVice Chair for Research, Department of Neurology Director, Division of Multiple Sclerosis and Translational Neuroimmunology
|
|
- Overview
- Education & Training
- Clinical Interests
- Committees & Organizations
- Research
- Research Opportunities
- Publications
Dr. Imitola is a Professor of Neurology, Genetics, and Neuroscience and is the Director of the Multiple Sclerosis (MS) Center, Chief of the Division of MS and Neuroimmunology, and Vice Chair of Research in the Department of Neurology at UConn Health. In collaboration with a multidisciplinary team, he has grown the clinical program for MS/Neuroinflammation and lifespan Neuroimmune disorders at UConn Health, making UConn Health a top choice for MS care in the state of Connecticut. The Program is now nationally recognized as a Comprehensive Center for MS care and a national leader in MS care in diverse populations. He is leading and creating novel innovative models of MS care to prevent progression in MS throughout the lifespan. Dr. Imitola has more than 165 papers, abstracts, and book chapters on stem cells and neuroinflammation primarily focusing on cortical damage in animal models of MS and the ethics of stem cell tourism. He has multiple accolades and awards, including the William Silen Award, John Whitaker Award, and the 2020 Inspiration Award from the National MS Society. He is a Fellow of the American Academy of Neurology (AAN) and the American Neurological Association (ANA). His work has been funded by NIH, the National MS Society, and industry grants.
Degree | Institution | Major |
---|---|---|
MD | University of Cartagena Faculty of Medicine | Medicine |
Post-Graduate Training
Training | Institution | Specialty |
---|---|---|
Internship | Hospital Militar Central, Columbia | Medicine |
Fellowship | Neurologic and Human Genetics Institute, Javeriana University, Columbia | Research and Clinical Fellow in Neurology and Genetics |
Postdoctoral | Brigham and Women’s Hospital, Harvard Medical School | Postdoctoral Fellow in Brain Tumor Biology, Neurosurgery |
Fellowship | Brigham and Women’s Hospital, Harvard Medical School | Research Fellow in Neurology |
Postdoctoral | Brigham and Women’s Hospital, Harvard Medical School | Postdoctoral Fellow in Multiple sclerosis and Neuroimmunology |
Residency | Temple University Hospital | Internal Medicine |
Residency | Temple University Hospital | Neurology (Chief 2011-2012) |
Fellowship | Thomas Jefferson University Hospital for Neuroscience | Multiple Sclerosis |
Certificate | Harvard Online/Harvard Business School | Certificate of Specialization in Health Care Leadership |
Awards
Name of Award/Honor | Awarding Organization |
---|---|
Sonnentag Distinguished Visiting Professor | Mayo Clinic Neuroscience and Neurosurgery |
American Academy of Neurology Annual Meeting (AANAM), Course Director “Diagnosis and Treatment of MS in Diverse population”. | American Academy of Neurology |
Selected as one of the Top Doctors in Connecticut (2021-2023) | Connecticut Magazine |
Peter B. Wade, MD Achievement Award | National MS Society |
Fellow of the American Neurological Association (FANA) | American Neurological Association (FANA) |
UConn Graduate Faculty Career Mentor of the Year Award (Student nominated) | UConn Center for Career Development. |
Volunteer Inspiration Award | National MS Society |
Dean's List | Ohio State University College of Medicine |
Selected as a Top Doctor | Central Ohio-Columbus Monthly |
Research Award for Outstanding Publication Faculty | Neurological Institute Ohio State University |
Research Grant Award | Neurological Institute Ohio State University |
Elected Fellow | American Academy of Neurology (ANN) |
Accepted into the Early Career Reviewer (ECR) Program | Center for Scientific Review (CSR), National Institutes of Health |
Research Grant Award | Neurological Institute Ohio State University |
Top Doctor | Castle and Connolly |
Distinguished MS - Montreal Lecturer | McGill University, Montreal |
The John N. Whitaker Prize for MS Research | ACTRIMS |
Distinguished Whitaker Scholar | ACTRIMS |
Resident Excellence in Teaching Award, Department of Neurology | Temple University School of Medicine |
Matthew T. Moore Neurology Resident Award, Department of Neurology | Temple University School of Medicine |
Gordon Neurology Resident Award, Department of Neurology | Temple University School of Medicine |
Gordon Neurology Resident Award, Department of Neurology | Temple University School of Medicine |
The Ruth and William Silen, M.D. Award | Biomedical Science Careers Program and Harvard Medical School |
Five Year Service Award | Brigham and Women's Hospital |
Selected Research for Highlights in the XIX Meeting | American Academy of Neurology |
M.D. With Distinction Top 5% of the Class | University of Cartegena Faculty of Medicine |
University Scholarship Award in Pharmcology | University of Cartegena Faculty of Medicine |
Dr. Imitola is a board-certified neurologist with clinical expertise in aggressive and progressive multiple sclerosis, late onset multiple sclerosis, neuromyelitis optica spectrum disorder, neurosarcoidosis, transverse myelitis, Susac syndrome, central nervous system vasculitis, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), neurologic complications of systemic autoimmunity and cancer immunotherapy, genetic mimics of multiple sclerosis such as adult leukodystrophies, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), and hereditary diffuse leukoencephalopathy with spheroids (HDLS).
Name & Description | Category | Role | Type | Scope | Start Year | End Year |
---|---|---|---|---|---|---|
UConn MD PHD Executive Committee | Advisory Committee | Member | University | 2022 | ||
International Society for Stem Cell Research (ISSCR). | Professional/Scientific Organization | Vice-Chair Education Committee | External | International | 2022 | |
FY21 CDMRP MSRP AP-1 multiple sclerosis peer review panel for the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP). | Study Section | Reviewer | External | International | 2021 | 2021 |
Ask an Expert: Aging in MS National MS Society English Version | Professional/Scientific Organization | Guest Speaker | External | National | 2020 | 2020 |
Ask an Expert: Aging in MS National MS Society Spanish Version | Professional/Scientific Organization | Guest Speaker | External | National | 2020 | 2020 |
COVID19 Vaccines for MS patients Taskforce | Professional/Scientific Organization | Member | External | National | 2020 | 2020 |
Invited Speaker for the National MS society Ask an Expert MS and AGING-SPANISH | Professional/Scientific Organization | Guest Speaker | External | National | 2019 | 2020 |
Ask an expert: COVID19 and MS National MS Society-SPANISH VERSION | Advisory Committee | Guest Speaker | External | National | ||
Panelist: Progressive MS in diverse population- Annual Meeting Scientific advisory board and Board of Directors | Professional/Scientific Organization | Guest Speaker | External | National | ||
MS Society CT-RI Chapter Board of Trustee | Advisory Committee | Trustee | Regional | |||
National Medical Advisory Committee MS Society | Advisory Committee | Member | External | National |
Dr. Imitola is a physician-scientist interested in progressive MS, neurodegeneration, and repair and has been studying these processes for the last 15 years. At the bedside, he is working on understanding the impact of social determinants of health in the biological progression of complex MS patients and real-world strategies for prevention of MS. At the bench, he leads a team that works on human models of neurological diseases using advanced, 3D stem cell cultures and bioengineering principles. With these techniques, he aims to identify new targets for next-generation medications for molecular prevention of neurodegeneration and improving repair in MS. His lab’s research can be explored through his lab website. At UConn Health, Dr. Imitola is a member of the MD-PhD executive committee that helps with training physician-scientists. He is member of the National MS Society National Medical Advisory Committee (NMAC) and on the Board of Trustees of the National MS Society, Connecticut-Rhode Island Chapter. He is the Vice Chair of the education committee at the International Society for Stem Cell Research (ISSCR), where he is focusing on stem cell education for clinicians around the world.
He has mentored and trained dozens of fellows, residents, and medical students, efforts that were recognized with the 2023 UConn Mentor of the Year Award.
Journal Articles
-
VISIBL-MS: A bilingual educational framework to increase awareness of early multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2024 Feb;13524585241228739
-
Patient-derived organoids recapitulate glioma-intrinsic immune program and progenitor populations of glioblastoma.
PNAS nexus 2024 Feb;3(2):pgae051
-
Double inversion recovery to detect cervical spinal cord multiple sclerosis lesions.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 2023 Mar;
-
Dysregulation of the chromatin environment leads to differential alternative splicing as a mechanism of disease in a human model of autism spectrum disorder.
Human molecular genetics 2023 Jan;
-
Development of Experimental Three-Dimensional Tumor Models to Study Glioblastoma Cancer Stem Cells and Tumor Microenvironment.
Methods in molecular biology (Clifton, N.J.) 2023 Jan;2572117-127
-
SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.
Journal of neuro-oncology 2023 Jan;161(1):67-76
-
Stat1 is an inducible transcriptional repressor of neural stem cells self-renewal program during neuroinflammation.
Frontiers in cellular neuroscience 2023 Jan;171156802
-
All anti-CD20 monoclonal antibodies have similar efficacy and risks: Commentary.
Multiple sclerosis (Houndmills, Basingstoke, England) 2022 Oct;28(12):1847-1848
-
Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Multiple sclerosis and related disorders 2021 May;53103021
-
The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies.
Neurology 2021 Apr;
-
Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab.
Multiple sclerosis and related disorders 2021 Feb;48102731
-
Generation of Neurosphere-Derived Organoid-Like-Aggregates (NEDAS) from Neural Stem Cells.
Current protocols 2021 Feb;1(2):e15
-
Preventive neurology concepts for training the next-generation and closing gaps in real-world Multiple Sclerosis Care.
Multiple sclerosis and related disorders 2020 Nov;47102631
-
Electrophysiological Maturation of Cerebral Organoids Correlates with Dynamic Morphological and Cellular Development.
Stem cell reports 2020 Sep;
-
Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy.
Mayo Clinic proceedings. Innovations, quality & outcomes 2020 Aug;4(4):443-459
-
Complications from "Stem Cell Tourism" in Neurology.
Annals of neurology 2020 Jul;
-
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
Multiple sclerosis (Houndmills, Basingstoke, England) 2020 Jun;1352458520925369
-
Aggressive multiple sclerosis (2): Treatment.
Multiple sclerosis (Houndmills, Basingstoke, England) 2020 Jun;1352458520924595
-
A possible link between intracranial lipomas and localization-related relapses in multiple sclerosis.
Multiple sclerosis and related disorders 2019 Nov;38101502
-
Convergence of human cellular models and genetics to study neural stem cell signaling to enhance central nervous system regeneration and repair.
Seminars in cell & developmental biology 2019 Nov;9584-92
-
Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation.
Nature communications 2019 Jan;10(1):217
-
PRMT5 as a druggable target for glioblastoma therapy.
Neuro-oncology 2018 May;20(6):753-763
-
A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.
Science translational medicine 2017 Dec;9(421):
-
iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases.
EMBO molecular medicine 2017 Dec;9(12):1742-1762
-
Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis.
Expert review of neurotherapeutics 2017 Jun;17(6):611-629
-
Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation.
JAMA neurology 2017 Apr;74(4):392-394
-
Big-Data-Driven Stem Cell Science and Tissue Engineering: Vision and Unique Opportunities.
Cell stem cell 2017 Feb;20(2):157-160
-
PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
Oncogene 2017 Jan;36(2):263-274
-
Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.
Journal of neurovirology 2016 Oct;22(5):683-687
-
Deletion 2q37 syndrome: Cognitive-behavioral trajectories and autistic features related to breakpoint and deletion size.
American journal of medical genetics. Part A 2016 Sep;170(9):2282-91
-
Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis.
JAMA neurology 2016 Aug;73(8):910-2
-
The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.
Neurology 2016 Jun;86(24):2303-9
-
Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.
Disease models & mechanisms 2016 Feb;9(2):199-210
-
Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis.
Glycobiology 2015 Dec;25(12):1392-409
-
A novel 2q37 microdeletion containing human neural progenitors genes including STK25 results in severe developmental delay, epilepsy, and microcephaly.
American journal of medical genetics. Part A 2015 Nov;167A(11):2808-16
-
Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor.
JAMA neurology 2015 Nov;72(11):1342-5
-
Rapid dissemination of granular cell astrocytoma arising from periventricular stem cell regions in chronic multiple sclerosis.
Journal of neuro-oncology 2015 Aug;124(1):147-9
-
Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.
Journal of immunology (Baltimore, Md. : 1950) 2015 Jun;194(11):5085-93
-
Use of Double Inversion Recovery from Brain MRI in detecting cervical spinal cord Multiple Sclerosis lesions.
Journal of Neuroimaging. 2023;00: 1-6. (NA):NA
Abstracts
Case Reports
-
Fraternal twins with autism, severe cognitive deficit, and epilepsy: diagnostic role of chromosomal microarray analysis.
Seminars in pediatric neurology 2014 Jun;21(2):167-71
Editorials
-
Regenerative neuroimmunology: The impact of immune and neural stem cell interactions for translation in neurodegeneration and repair.
Journal of neuroimmunology 2019 Jun;3311-3
-
New age for progressive multiple sclerosis.
Proceedings of the National Academy of Sciences of the United States of America 2019 Apr;116(18):8646-8648
-
Is no evidence of disease activity a realistic goal for patients with multiple sclerosis?
JAMA neurology 2015 Feb;72(2):145-7
-
The cerebrospinal fluid-stem cell interactions as target for regenerative therapy in neurological diseases.
Stem cells and development 2015 Jan;24(2):145-6
Letters
-
Letter in Reply: Toward a COVID-19 Vaccine Strategy for Pemphigus Patients on Rituximab.
Journal of the American Academy of Dermatology 2020 Oct;
Reviews
-
Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis.
Current opinion in pharmacology 2022 Feb;63102184
-
Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration.
Stem cells translational medicine 2015 Mar;4(3):252-60